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Regulatory T cells suppress inflammation and promote tissue repair in multiple contexts. Proto, Doran, et al. show that Treg cells enhance the ability of macrophages to engulf apoptotic cells (efferocytosis) and thereby promote resolution of inflammation.
INTRODUCTION
A program known as inflammation resolution dampens inflammation and promotes tissue repair during and after the host response to pathogens and tissue injury (Buckley et al., 2014) . Resolution is mediated by protein and lipid mediators secreted by inflammatory cells. These mediators bind specific receptors on effector cells, notably leukocytes and myofibroblasts, leading to the activation of various resolution and repair pathways. A key process in the resolution response is the phagocytosis of apoptotic cells, known as efferocytosis, which prevents apoptotic cells from becoming necrotic and pro-inflammatory (Godson et al., 2000; Buckley et al., 2014; Arandjelovic and Ravichandran, 2015) . Pro-resolving mediators have been shown to promote efferocytosis in cultured macrophages and in a variety of disease models in vivo, including acute peritonitis, lung injury, and atherosclerosis (Serhan et al., 2014) . Moreover, signaling through certain efferocytosis receptors can inhibit inflammatory signaling pathways and promote the secretion of resolution mediators (Fadok et al., 1998; Freire-de-Lima et al., 2006; Cai et al., 2016) . Thus, efferocytosis plays a critical, amplifying role in the resolution response such that it acts as both an effector and a source of resolution mediators.
The role of T cells in resolution is emerging as a critically important topic, and most studies focus on how resolving mediators affect T cell biology. For example, lipoxins and T helper 2 (Th2)-cell-derived protectin D1 suppresses T cell pro-inflammatory cytokines and infiltration into inflammatory sites (Buckley et al., 2014) . Conversely, pro-inflammatory leukotriene B 4 (LTB 4 ) has been shown to dose-dependently decrease the differentiation of naive T cells into regulatory T (Treg) cells, favoring instead the generation of Th17 cells (Chen et al., 2009) . The topic of Treg cells is highly relevant because they secrete proteins, such as interleukin-10 (IL-10) and amphiregulin, that promote tissue repair (D'Alessio et al., 2009; Weirather et al., 2014; Arpaia et al., 2015) . However, remarkably little is known about how specific resolution processes are affected by Treg cells. In this context, we sought to identify whether Treg cells can promote efferocytosis and, if so, to elucidate key mechanisms. We now show both in vitro and in vivo that Treg cells can indeed boost the ability of macrophages to carry out efferocytosis during resolution responses. A key mechanistic component involves the induction of IL-10 in macrophages by Treg-cell-derived IL-13. IL-10, via an autocrine-paracrine pathway that affects the guanine nucleotide exchange factor (GEF) Vav1 and the GTPase Rac1, enables macrophages to optimally internalize apoptotic cells. Enhancement of macrophage efferocytosis by Treg cells was evident in three models of inflammation, including atherosclerosis, a critically important disease process characterized by defects in Treg cells, efferocytosis, and resolution. These findings reveal a specific role for Treg cells in inflammation resolution and tissue repair and thereby add to the mechanistic basis for the development of Treg-cell-enhancing therapy for chronic inflammatory diseases.
RESULTS

Treg Cell Depletion Reduces the Efferocytic Capacity of Peritoneal Macrophages during Resolution of Inflammation
To test the hypothesis that Treg cells promote efferocytosis during inflammation resolution, we began with a well-established model of acute inflammation and its resolution, zymosaninduced peritonitis. Low-dose zymosan (0.1 mg) elicits a neutrophil-mediated inflammatory response followed by a decrease in neutrophil numbers and a sharp increase in Treg cells (Newson et al., 2014) . We reasoned that this two-phase response might involve Treg-cell-mediated enhancement of efferocytosis of dying neutrophils by macrophages during the resolution phase. Accordingly, we asked whether Treg cell depletion at the onset of resolution would reduce macrophage efferocytic capacity in this model. To accomplish this goal, we depleted Treg cells by injecting diphtheria toxin (DT) into mice expressing the human DT receptor driven by the Foxp3 promoter (Foxp3-hDTR mice) (Saito et al., 2001) . DT or PBS was given on days 4, 6, and 8 after zymosan injection. On day 11, when Treg cell numbers typically peak (Newson et al., 2014) , we found that peritoneal fluid Treg cells were markedly depleted in DT-treated mice ( Figure 1A ). In contrast, macrophage numbers were not statistically different between the two groups of mice ( Figure 1B) . In order to evaluate the efferocytic capacity of peritoneal macrophages in vivo, we injected the peritoneum with fluorescently labeled apoptotic neutrophils. After 45 min, the peritoneal cells were collected by lavage and analyzed by flow cytometry. Uptake of the injected apoptotic neutrophils by peritoneal F4/80 + macrophages in
Treg-cell-depleted mice was $50% lower than that in PBStreated control mice ( Figure 1C ). These data suggest that Treg cells play an important role in the clearance of apoptotic cells during the resolution phase of zymosan-induced peritonitis.
Treg Cell Depletion during the Resolution Phase after Acute Lung Injury Reduces Efferocytosis by Airspace Macrophages Treg cells are required for timely inflammation resolution in lipopolysaccharide (LPS)-induced acute lung injury (ALI) (D'Alessio et al., 2009) . Moreover, murine models and clinical data suggest that efficient efferocytosis following injury is critical for lung repair (Schmidt and Tuder, 2010) . In order to determine whether Treg cells promote macrophage efferocytosis during ALI, we subjected Foxp3-hDTR mice to LPS-induced ALI. Mice were treated with intranasal LPS on day 0 and then given DT injections (or PBS) on day 1 or days 1, 3, and 5. Figure 2C ) and did not lead to any changes in blood leukocyte numbers (Figure S1A ). In the experiment in which mice were injected with PBS or DT on days 1, 3, and 5, histopathologic injury scoring (Matute-Bello et al., 2011) by a blinded observer revealed that there was a trend toward improvement in the control mice between days 4 and 7 on the basis of neutrophil numbers in alveolar and interstitial spaces, airway debris, and alveolar septal thickening ( Figures S1B and S1C ). This improvement was not Foxp3-human DTR mice were injected i.p. with 0.1 mg zymosan at day 0 and then with 50 mg/kg DT at day 4 and 15 mg/kg DT at days 6 and 8. The vehicle control for DT was PBS. (A and B) Peritoneal lavage fluid of one cohort of DT-and PBS-treated mice sacrificed at day 11 was analyzed for Treg cells, either as a percentage of CD4 cells that were CD25 + Foxp3 + or as an absolute number per mouse, and for the total number of peritoneal F4/80 + macrophages (n = 7 mice per group; *p < 0.05, two-tailed Student's t test; n.s., non-significant). Data displayed represent one of five independent experiments and are means ± SEM. (C) At day 11, another cohort of DT-and PBStreated mice was injected i.p. with PKH-redlabeled apoptotic cells (ACs), and 45 min later lavage fluid was analyzed by flow cytometry for the percentage of F4/80 + macrophages that had incorporated the labeled neutrophils (n = 4 orseen in the Treg-cell-depleted mice, resulting in a significantly worse histological score in these mice than in control mice at day 7.
As a prelude to assaying efferocytosis, we assayed dead cell content in the above day-1-3-5 DT experiment and found that the number of apoptotic cells, assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), declined between days 4 and 7 in control mice, consistent with efficient efferocytosis. In contrast, the number of apoptotic cells remained elevated in Treg-cell-depleted mice at day 7 (Figure 2D ). To directly examine efferocytosis in day 4 lung tissue, we quantified the ratio of TUNEL + nuclei (dead cells) associated with Mac-3 + macrophages to dead cells not associated with macrophages (''free'') ( Thorp et al., 2008) . The data showed that Treg cell depletion significantly reduced efferocytosis (Figures 2E and S1D [top] 
Treg Cell Depletion Disrupts Apoptotic Cell Internalization and Rac1 Activation in Macrophages
In preparation for mechanistic studies of how Treg cell depletion decreases efferocytosis, we first determined whether we could recapitulate the Treg-cell-depletion-mediated defect in efferocytosis ex vivo. To that end, peritoneal macrophages were isolated from PBS-or DT-treated Foxp3-hDTR mice 11 days after zymosan and then incubated ex vivo with fluorescently labeled apoptotic cells at 37 C. The macrophages from DT-treated mice showed lower efferocytosis than macrophages from control mice ( Figure 3A , left). We next conducted this experiment at 4 C, which allows apoptotic cell binding but prevents uptake. Macrophages from control and DT mice showed equal apoptotic cell binding ( Figure 3A, right) , suggesting that the Figure S2 (n = 4 or 5 mice per group; *p < 0.05, two-tailed Student's t test). Data displayed represent one of two independent experiments and are means ± SEM. Please also see Figure S1 .
defect in efferocytosis in macrophages from Treg-cell-depleted mice was due to impaired engulfment (not binding) of apoptotic cells. Apoptotic cell engulfment converges on Rho-family GTPase activation, which induces cytoskeletal rearrangement. In particular, Rac1 has been shown to be critical for apoptotic cell engulfment as well as for the internalization of other phagocytic cargo (Ravichandran and Lorenz, 2007) . Rac1-GTP increases early after apoptotic cell recognition by membrane receptors, and active Rac1 is recruited to the phagocytic cup, where it promotes F-actin assembly. Thus, we questioned whether macrophages from Treg-cell-depleted mice might have decreased GTP-bound Rac1, a measure of Rac1 activity, during phagocytosis. In pilot experiments, we found a high degree of variability in the assay of Rac1 activity in macrophages incubated with apoptotic cells, perhaps as a result of the effect of proteins in the apoptotic cells themselves. We reasoned that using inert beads as the phagocytic substrate might minimize this problem. We first determined whether macrophages from DT-treated mice had a defect in the uptake of polystyrene beads ex vivo, which indeed was the case ( Figure S2A ). Using this model, we compared Rac1 activation in macrophages from control and DT mice. Whereas GTP-bound Rac1 was significantly increased 20 min after the addition of beads in control macrophages, the bead-induced increase in Rac1 activation was completely abrogated in macrophages from Treg-cell-depleted DT mice ( Figure 3B ). Thus, preventing macrophages from being exposed to Treg cells during resolution impairs efferocytosis and phagocytosis-associated Rac1 activation.
We next asked whether a Treg-cell-macrophage co-culture model could recapitulate some of these findings. For this purpose, bone-marrow-derived macrophages were incubated for 48 hr with or without splenic Treg cells ( Figure S2B ) and then assayed for the uptake of fluorescently labeled apoptotic Jurkat cells and for bead-induced Rac1 activation. Consistent with the previous data, Treg cells enhanced apoptotic cell uptake without altering binding and increased bead-induced Rac1 activation ( Figures 3C and 3D ). We also investigated whether Treg-cell-macrophage co-culture would induce other macrophage changes suggestive of a more pro-resolving phenotype. Indeed, Treg cells led to an upregulation in macrophages of mRNAs for genes associated with resolution, including Arg1, Retnla (Fizz1), and Mrc1 (CD206) ( Figure S2C ). We also compared mRNA from peritoneal macrophages obtained from mice at day 8 after zymosan injection, which is prior to the influx of Treg cells, with macrophages at day 10, which is the time when Treg cell influx into the peritoneum reaches its peak. Day 10 macrophages showed decreased expression of the pro-inflammatory genes Il1b and Il6 and increased expression of the pro-resolving gene Mrc1 (CD206), and there were trends toward decreased Tnfa and increased Arg1 ( Figure S2D ). In summary, Treg cells can directly enhance the ability of macrophages to internalize apoptotic cells or a non-cellular phagocytic substrate, and this action of Treg cells is associated with activation of Rac1. In line with the role of efferocytosis in resolution, Treg cells might also shift the phenotype of macrophages toward a more general pro-resolving functional state. 
Enhancement of Efferocytosis by Treg Cells Involves
Treg-Cell-Induced Macrophage IL-10 Production A number of secreted molecules, including IL-10, have been described to be important for Treg cell function (Arpaia et al., 2015) . Because IL-10 enhances efferocytosis by macrophages (Ogden et al., 2005; Michlewska et al., 2009; Michalski et al., 2016) , we investigated whether it is required for Treg-cell-mediated enhancement of macrophage efferocytosis. Using the zymosan peritonitis model, we first compared the efferocytic capacity of peritoneal macrophages from Il10 À/À and WT mice in vivo. On day 11 after zymosan injection, WT and Il10 À/À mice were injected intraperitoneally (i.p.) with fluorescently labeled apoptotic neutrophils, and after 45 min, uptake of the labeled cells by exudate macrophages was evaluated by flow cytometry. We found that apoptotic cell uptake was lower in Il10 À/À mice than in WT mice ( Figure 4A ). Of note, there was no difference in the percentage of peritoneal Treg cells (CD4 + CD25 + ) between WT and Il10 À/À mice ( Figure S3A ). As further validation, a neutralizing anti-IL-10 antibody injected i.p. 48 hr before the harvest of peritoneal macrophages also caused a reduction in ex vivo efferocytosis ( Figure 4B ). To determine whether Treg cells are the source of efferocytosisenhancing IL-10, we injected WT or Il10 À/À splenic Treg cells into the peritoneum of naive WT mice. After 3 days, macrophages harvested from the peritoneal exudates of these mice were assayed for uptake of labeled apoptotic cells. We found that that injection with WT and Il10 À/À Treg cells enhanced subsequent ex vivo efferocytosis similarly ( Figure 4C ), suggesting that IL-10 production by Treg cells is dispensable for this process. We next tested whether expression of IL-10 by macrophages is required for the ability of Treg cells to enhance efferocytosis. For this purpose, WT and Il10 À/À bone-marrow-derived macrophages were cultured with WT splenic Treg cells and then assayed for efferocytosis in vitro. Whereas Treg cells enhanced efferocytosis in WT macrophages as expected, they did not have this effect on Il10 À/À macrophages ( Figure 4D ) or on macrophages from mice lacking the b subunit of the IL10 receptor (Il10rb
), which is required for IL-10 signaling (Spencer et al., 1998;  Figure S3B ). Similar results were found when the endpoint of this assay was bead-mediated Rac1 activation ( Figure 4E ). Thus, Treg-cell-mediated enhancement of efferocytosis requires macrophages to express both IL-10 and the IL-10 receptor, suggesting an autocrine-paracrine pathway in which Treg-cell-stimulated macrophage IL-10 production enhances apoptotic cell internalization by IL-10-mediated Rac1 activation in macrophages.
To provide further support for this hypothesis, we showed that incubation of cultured macrophages with Treg cells markedly increased the expression of Il10 mRNA in the macrophages and the expression of the macrophage IL-10 target gene Bcl3 in WT but not Il10 À/À macrophages ( Figure 4F ).
Consistent with the findings above, Treg-cell-induced Il10 and Bcl3 in macrophages did not depend on IL-10 expression by the Treg cells ( Figures S3C and S3D ). Finally, incubation of macrophages with recombinant IL-10 enhanced efferocytosis without increasing apoptotic cell binding (Figures 4H and S3E) and increased Rac1 activation ( Figure 4H ). IL-10 also enhanced efferocytosis in human macrophages ( Figure S3F ). These combined data support a mechanism in which Treg cells send a transcellular signal that induces Il10 in macrophages and then IL-10 acts in an autocrine-paracrine manner in macrophages to enhance Rac1-mediated apoptotic cell internalization.
The Treg-Cell-IL-10-Efferocytosis Pathway Is Functional in a Complex Inflammatory Disease Model In atherosclerosis, the disease process underlying the leading causes of death in the industrialized world, defective efferocytosis and decreased Treg cells drive disease progression, but these two processes have not been previously linked (Schrijvers et al., 2005; Yurdagul et al., 2018; Ait-Oufella et al., 2006) . In this context, we focused on the specific question as to whether expansion of Treg cells during advanced atherosclerosis progression can promote lesional efferocytosis in an IL-10-dependent manner. 12-week-old Western-diet (WD)-fed Ldlr
mice, which develop aortic root atherosclerotic lesions with defective efferocytosis (Thorp et al., 2008) , were treated with IL-2 complex (IL-2C) consisting of recombinant IL-2 and anti-IL-2 monoclonal antibody to expand Treg cells (Boyman et al., 2006; Dinh et al., 2012; Foks et al., 2011) . The complex was administered for 3 consecutive days and then once every 5 days thereafter for a 3-week period, during which time the WD was continued. Some of the mice were also treated twice weekly during this 3-week period with an anti-IL-10 neutralizing antibody, and the rest of the mice received control IgG antibody. 5 days after the initiation of IL-2C treatment, there was >5-fold elevation of circulating Treg cells, and this was unaffected by anti-IL-10 co-administration ( Figure 5A ). At the time of sacrifice, Treg cells were also significantly higher in the spleens of IL-2C-treated mice ( Figure 5B ). We also measured phospho-STAT3 in splenocytes by flow cytometry as a measure of IL-10 bioactivity and found that this endpoint was significantly increased by IL-2C but not by the combination of IL-2C and anti-IL-10 ( Figure 5C ). Treg cell expansion with or without IL-10 neutralization had no effect on body weight, plasma cholesterol, plasma triglycerides, or fasting glucose ( Figures S4A-S4D) . Moreover, as expected for this short treatment period, there were no differences in lesional area or macrophage content among the four groups ( Figures S4E and S4F) . However, as predicted by the hypothesis, IL-2C treatment significantly improved the ratio of macrophage-associated to macrophage-free apoptotic cells, indicating enhanced efferocytosis, and this improvement was abrogated by IL-10 neutralization ( Figure 5D ). The improvement in efferocytosis in the IL-2C group (second group) and the prevention of this effect in the anti-IL-10 group (third group) could not be explained by changes in cell death because the total number of TUNEL + lesional cells was similar among these two groups and the Veh-IgG control group (first group) ( Figure S4G ). Although the number of apoptotic cells was modestly higher in the lesions of mice treated with anti-IL-10 alone (fourth group), the data in Figure 5D show that lesional efferocytosis was similar between this group and the control group (representative images are shown in Figure S4H ). These data support the conclusion that Treg cell expansion can enhance efferocytosis in an IL-10-dependent manner in a critically important disease model that encompasses both decreased Treg cells and defective efferocytosis. (H) Bone-marrow-derived macrophages were pre-treated for 48 hr with 10 ng/mL rIL-10 and then assayed for GTP-bound Rac1 10 min after exposure to beads as in Figure 4D (n = 3 wells; *p < 0.001 versus no beads and **p < 0.001 for rIL-10 versus Veh, two-way ANOVA, Sidak's multiplecomparisons test). Data displayed represent one of two independent experiments and are means ± SEM. Please also see Figure S3 .
findings were obtained when a Transwell system was used to separate the macrophages and Treg cells, indicating that Treg-cell-macrophage contact was not needed for Treg-cellinduced efferocytosis in macrophages ( Figure 6D, right) or when an anti-IL-13 neutralizing antibody was used instead of Il13 À/À Treg cells ( Figure S5B ). However, when IL-13 was silenced in macrophages, WT Treg cells still enhanced macrophage IL-10 expression ( Figure S5C ), indicating that Treg-cellderived IL-13 rather than macrophage-derived IL-13 is important in this pathway. Finally, we examined the effect of WT and Il13
Treg cells on the uptake of polystyrene beads, live cells, and heat-induced necrotic cells. As with apoptotic cells, Treg cells increased the uptake of polystyrene beads in an IL-13-dependent manner ( Figure S5D , left graph), which is consistent with the finding that Treg cells stimulate efferocytosis via Rac1-mediated internalization. As expected, there was no detectable uptake of live cells by macrophages, and this did not change when Treg cells were added. Necrotic cell uptake by macrophages was substantial even without co-culture with Treg cells and was not further enhanced by Treg cells ( Figure S5D , right graph).
To assess the role of IL-13 in vivo, we turned to the peritoneal adoptive-transfer model described in Figure 4B and found that enhancement of efferocytosis by i.p. injected Treg cells was abrogated when the mice were co-injected with anti-IL-13 neutralizing antibody at the time of Treg cell injection ( Figure 6E ). In addition, we utilized the Foxp3-hDTR mouse model and showed that whereas WT Treg cells were able to rescue deficient efferocytosis in Treg-cell-depleted mice, delivery of an equal number of Il13 À/À Treg cells failed to do so ( Figures 6F and   S5E ). We then tested this pathway in a disease model by utilizing the LPS-induced model of acute lung injury in Foxp3-hDTR mice described in Figure 2 . As expected, DT treatment caused a loss of Treg cells in both the lungs and spleen ( Figure S5F , groups 1 and 2), and consistent with our previous experiment, the lungs of mice depleted of Treg cells had lower efferocytosis than those of control mice ( Figure 6G , groups 1 and 2). We then tested the effect of partially restoring the lungs of DT-treated mice with WT versus Il13 À/À Treg cells by using the strategy described for Figure 6G , groups 3 and 4). We next questioned whether different types of macrophages might respond differently to Treg cell stimulation. It has been reported previously that resident macrophages have higher rates of efferocytosis than do recruited macrophages (Newson et al., 2014) . Accordingly, we isolated resident peritoneal macrophages from naive mice (day 0 macrophages) and from mice that had received 0.1 mg of zymosan (a source of predominantly recruited macrophages) 8 days previously. These macrophages were co-cultured ex vivo with either WT or Il13 À/À Treg cells for 48 hr and then assayed for efferocytosis. As predicted, day 0 macrophages were better efferocytes under basal conditions. Most importantly, whereas both day 0 and day 8 macrophages showed enhanced efferocytosis in response to WT Treg cells, the day 0 macrophages demonstrated a 20.1% increase, and the day 8 macrophages demonstrated a 66.4% increase (Figure S6A , groups 1 and 2 and groups 4 and 5). In contrast, (D) Aortic root lesions of the four groups of mice were assayed for in situ efferocytosis by quantification of the ratio of apoptotic cells (ACs) that were associated with lesional macrophages or not (free) (n = 7-13 mice per group; *p < 0.05 versus all other groups, one-way ANOVA, Sidak's multiple-comparisons test). Data represent means ± SEM. Please also see Figure S4 .
Il13
À/À Treg cells failed to boost efferocytosis in either day 0 or day 8 macrophages ( Figure S6A , groups 3 and 6). Given the role for both Treg cell IL-13 and macrophage IL-10, we sought to determine whether these are dynamically regulated in the peritonitis model. Day 4 and 10 post-zymosan-injection mice were examined, during which time Treg cells showed a marked increase and macrophages showed a slight decrease ( Figure S6B ). As predicted by the proposed pathway, IL-13 in the peritoneal exudate rose between days 4 and 10 ( Figure S6C ). Note that the expression of Il13 by Treg cells did not rise ( Figure S6D) , consistent with the idea that the increased number of Treg cells in the peritoneum at day 10 rather than the increased production per cell is responsible for the observed increase in peritoneal IL-13. Three other predictions were borne out by the data: (1) the concentration of peritoneal IL-10 rose between days 4 and 10 ( Figure S6E ), (2) this rise coincided with an increase in Il10 expression by macrophages (Figure S6F) , and (3) the expression of Il13 in macrophages and Il10 in Treg cells did not change over time (Figures S6G and S6H) .
In summary, the combined in vitro and in vivo data support a pathway in which activated Treg cells secrete IL-13, which then increases efferocytosis by stimulating macrophages, particularly recruited macrophages, to secrete the efferocytosis-enhancing autocrine-paracrine cytokine IL-10. The finding that Il13 À/À Treg cells had some ability, albeit minimal, to boost Peritoneal macrophages from these mice were than assayed for efferocytosis ex vivo (n = 6 wells; *p < 0.05 versus the other groups, one-way ANOVA, Sidak's multiple-comparisons test). Data represent means ± SEM. (F) Naive Foxp3-human DTR mice were injected with PBS or 50 mg/kg DT at day 0 and then 15 mg/kg DT on the morning of day 1. On the afternoon of day 1, 5 3 10 efferocytosis in the DT lung model suggests that Treg cells have an additional pro-efferocytic mechanism in this setting.
IL-10 Signaling Enhances Apoptotic Cell Uptake via Induction of Vav1
As a Rho family GTPase, Rac1 cycles between an active GTPbound form and an inactive GDP-bound form through the action of GEFs. In considering how IL-10 enhances Rac1 activity to enhance efferocytosis (Figure 3) , we focused on the Rac1 GEF Vav1. Vav1 has been implicated previously in efferocytosis and is a target of STAT3, which is one of the mediators of IL-10 transcriptional programming (Mondal et al., 2011; Hutchins et al., 2012) . We found that IL-10 increased Vav1 expression in macrophages and that this increase was blocked by the STAT3 inhibitor Stattic (Schust et al., 2006) (Figures 7A and S7A ). Vav1 expression was also induced by Treg cells, and this effect was dependent on IL-10 expression by the macrophages ( Figure 7B ). To determine the importance of Vav1 in IL-10-enhanced efferocytosis, we used small interfering RNA (siRNA) to silence Vav1 in macrophages ( Figure S7B ) and then tested the effect of IL-10 on efferocytosis and Rac1 activation. Vav1 silencing completely abrogated the enhancement of both efferocytosis and Rac1 activation by IL-10 ( Figures 7C and 7D) . Together, the data in Figures 3, 4 , 5, 6, and 7 support a mechanism in which Treg cells enhance macrophage efferocytosis through a transcellular signaling pathway in which Treg-cell-derived IL-13 activates an IL-10-Vav1-Rac1 apoptotic cell internalization pathway in macrophages ( Figure S7C ).
DISCUSSION
Treg cells, by suppressing the inflammatory activity of both innate and adaptive immune cells and by secreting proteins involved in tissue repair, are poised to play an important role in the inflammation resolution response (Gagliani et al., 2015; Newson et al., 2014; D'Alessio et al., 2009; Weirather et al., 2014; Arpaia et al., 2015) . Our findings showing that Treg cells boost efferocytosis by macrophages, which is a critically important effector arm of inflammation resolution, fits this idea well. Treg cells carry out this function by using IL-13 as a transcellular mediator: Treg-cell-derived IL-13 stimulates macrophages to produce IL-10, which then acts in an autocrine-paracrine manner to enhance apoptotic cell engulfment via a Vav1-Rac1-mediated mechanism. IL-13 is typically considered to be pro-inflammatory, but it has also been reported to stimulate IL-10 production and inflammation resolution in a murine model of chronic colitis (Fichtner-Feigl et al., 2014) and to be protective in experimental autoimmune encephalomyelitis (Ochoa-Repá raz et al., 2008) . Although IL-13 appears to be the dominant mechanism in vitro and in zymosan-induced peritonitis, it is possible that Tregcell-mediated enhancement of efferocytosis in other settings might involve additional mechanisms, as suggested by our finding that adoptive transfer of Il13 À/À Treg cells into the lungs of Treg-cell-depleted mice led to higher lung macrophage efferocytosis than vehicle alone. Thus, it is possible that Treg cells in this model might secrete a protein, in addition to IL-13, that increases macrophage IL-10 (Chung et al., 2007) or that enhances macrophage efferocytosis by an IL-10-independent mechanism. Although the Treg-cell-efferocytosis pathway revealed here has not been previously elucidated, the IL-10 component of this pathway integrates well with the results of previous studies (Ogden et al., 2005; Michlewska et al., 2009; Michalski et al., 2016) . One of these studies suggests a mechanistic link to STAT3 activation (Michalski et al., 2016) , which fits well with Please also see Figure S7 . the STAT3-Vav1-Rac1 pathway reported here. Another paper reported that Treg cell depletion during ALI is associated with an increase in protein and neutrophils in bronchoalveolar lavage fluid and a worsening of lung histology (Aggarwal et al., 2014) , but efferocytosis was not examined. Finally, in considering the findings here, it is interesting to consider how the ability of Treg cells to induce macrophage IL-10 might have a broader role in macrophage-mediated inflammation resolution. For example, a recent report shows that IL-10 can re-program macrophage metabolism in a way that promotes anti-inflammatory and resolution functions (Ip et al., 2017) .
The application of our findings to atherosclerosis has particularly important implications. Defective resolution in general and defective efferocytosis in particular play key roles in the progression of relatively benign atherosclerotic lesions into clinically important necrotic plaques (Serhan et al., 2014; Schrijvers et al., 2005; Yurdagul et al., 2018) . Moreover, animal and human studies suggest that Treg cells, IL-10, and IL-13 can protect against advanced plaque progression (Schrijvers et al., 2005; Yurdagul et al., 2018; Ait-Oufella et al., 2006; Pinderski et al., 2002; Potteaux et al., 2004; Liu et al., 2006; George et al., 2012; Tziakas et al., 2007; Cardilo-Reis et al., 2012) . Our current data now suggest a plausible link among defects in Treg cells, IL-10, IL-13, and efferocytosis in plaque progression and thereby raise the possibility that therapeutically boosting this axis might prevent atherothrombotic disease in subjects at high risk. Likewise, on the basis of the other two in vivo models used in this study, this therapeutic strategy could help prevent the pathophysiological consequences of sepsis and inflammatory lung disease, which, like advanced atherosclerosis, are often associated with impaired resolution (Buckley et al., 2014) .
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Ira Tabas (iat1@cumc.columbia.edu). An MTA was obtained for the transfer of Il13 À/À mice.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines Jurkat (human T lymphocytes) and L-929 (mouse fibroblasts) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (HI-FBS), and 10 U/mL penicillin and 100 mg/mL streptomycin. Cells were cultured in a humidified CO 2 incubator at 37 C.
Primary Cell Cultures
For bone marrow-derived macrophages (BMDMs), bone marrow cells from 8-12 week old male or female mice were cultured in DMEM supplemented with 10% (vol/vol) heat-inactivated FBS, 10 U/mL penicillin, 100 mg/mL streptomycin, and 20% (vol/vol) L-929 fibroblast-cultured media supernatants for 7-9 days (Thorp et al., 2008) . For human macrophages, buffy coats were purchased from the New York Blood Donor Center, and peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep according to the manufacturer's instructions. Briefly, Lymphoprep was added to the bottom of 50-mL Sepmate conical tubes, and buffy coat (diluted 1:1 with PBS containing 2% FBS) was layered above. Tubes were centrifuged at 800 3 g for 20 min at room temperature to collect the mononuclear cell fraction. Approximately 60 million PBMCs were plated on 10-cm Petri dishes. After 1 hr, non-adherent cells were removed by washing, and the adherent cells were cultured with Roswell Park Memorial Institute 1640 media (RPMI-1640) supplemented with 10% FBS and 10 ng/mL recombinant human GM-CSF for 7 days, with the medium replaced after the first 3 days. Columbia University Institutional Review Board and Health Insurance Portability and Accountability Act guidelines were followed for isolating peripheral human blood monocytes.
Experimental Animals
Animal protocols were approved by Columbia University's Institutional Animal Care and Use Committee. All animals were cared for according to the NIH guidelines for the care and use of laboratory animals. Mice were socially housed under a 12-hour light-dark cycle with ad libitum access to water and food. All mice were on the C57BL/6J background. C57BL/6J (WT), B6.129S7-
) mice were purchased from Jackson Laboratories. Il13 À/À mice were a generous gift from Andrew
McKenzie at the MRC Laboratory of Molecular Biology in Cambridge, UK (Neill et al., 2010) . Male and female mice between the ages of 8-20 weeks were used in this study, and all mice were assigned randomly to the various experimental groups.
METHOD DETAILS
Zymosan-Induced Peritonitis Peritonitis was induced by i.p. injection of 0.1 mg zymosan A in a 500 mL volume per mouse (day 0). Treg cells were depleted in Foxp3-human DTR mice by i.p. injection of diphtheria toxin at day 4 (50 mg/kg), day 6 (15 mg/kg), and day 8 (15 mg/kg). Mice were sacrificed on day 11, and peritoneal exudates were collected by lavage with 2 mL of sterile PBS.
Peritoneal Uptake of Labeled Apoptotic Cells (ACs) Neutrophils were collected by peritoneal lavage from donor mice 6 hr after they had been injected with 1 mg of zymosan A. The lavage fluid was passed through a 40-mm strainer and washed, and neutrophils were isolated with the EasySep Mouse Neutrophil Enrichment Kit according to manufacturer's instructions and then cultured overnight in medium containing 1% FBS and 1% penicillin and streptomycin in DMEM. On the following day, the neutrophils, which were now apoptotic, were labeled with PKH26 red according to the manufacturer's instructions. The recipient mice were injected i.p. with 4 3 10 6 of these labeled apoptotic cells, and 45 min later, the mice were sacrificed and the peritoneum was lavaged. Efferocytosis was quantified as the percentage of F4/80 + macrophages that had taken up one or more PKH-labeled apoptotic cells. Acute Lung Injury LPS (3.75 mg/g body weight) was delivered by intranasal installation (day 0). To deplete Treg cells in DT-Treg cell mice, 50 mg/kg body weight diphtheria toxin was delivered i.p. at day 1. Alternatively, Treg cells were depleted in WT mice by injection of 0.5 mg anti-CD25 antibody at days À2 and +1. For cells in which Treg cells were administered to mice, 2 3 10 6 cells were resuspended in 40 mL of PBS and delivered intranasally to anesthetized mice. Four days post-LPS, mice were sacrificed, blood was removed by cardiac puncture, and the vasculature was perfused with PBS. Lungs were either lavaged with PBS, fixed by gravity perfusion of formalin, or harvested, minced, and digested with Liberase TL for 30 min at 37 C, followed by staining for flow cytometry. For 7-day experiments, mice were given additional doses of diphtheria toxin (15 mg/kg body weight) at days 3 and 5 post-LPS.
Lung Histology
Formalin-fixed lung tissues were paraffin-embedded and then sectioned. Tissue sections were stained with hematoxylin and eosin, then examined and quantitatively analyzed using a Nikon Labphoto 2 microscope equipped with Image Pro Plus software. Injury scoring was conducted by a blinded observer according to a previously established method (Matute-Bello et al., 2011) . Briefly, images were scored for neutrophil localization to the alveolar and interstitial spaces, as well as the presence of air space debris and alveolar septal thickening.
In Situ Efferocytosis Analysis
Efferocytosis was determined using previously described methods (Thorp et al., 2008) . Apoptotic cells were identified in tissue sections by performing terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) using the tetramethylrhodamine red in situ cell death detection kit according to the manufacturer's protocols. Frozen tissues were first fixed with ice-cold acetone for 3 min at À20
C. In the case of formalin-fixed paraffin embedded tissues, tissues were first deparaffinized and incubated with proteinase K solution according to the manufacturer's instructions. Following TUNEL staining, sections were incubated with primary antibodies against Mac3 or F4/80, and then by Alexa Fluor 647-or Alex Fluor 488-conjugated secondary antibodies to identify macrophages. Images were captured using a Leica DMI 6000B or an Olympus IX-70 microscope and analyzed using ImageJ software. Briefly, the number of apoptotic cells that co-localized with or were adjacent to macrophages (''associated'') and those that were not associated with macrophages (''free'') were counted. Efferocytosis efficiency was quantified based on the ratio of associated:free apoptotic cells per tissue section.
Flow Cytometry
Cells were washed, resuspended in staining buffer consisting of 2% FBS in PBS with 2 mM EDTA, blocked with anti-mouse CD16/32 antibodies for 10 min, and then incubated with primary antibodies. Treg cells in bronchoalveolar lavage samples from Foxp3 GFP/DTR mice were identified by first immunostaining for CD4 or CD3 and then by assaying eGFP expression among these cells. To analyze splenic T cells, spleens were processed to form a single-cell suspension and then placed through a 40-mm filter. Following red blood cell lysis, cells were blocked and stained for CD4 and CD25. Alternatively, following surface staining, cells were incubated with fixation-permeablization buffer, washed with permeabilization buffer, and then incubated with Foxp3 antibody. Peripheral blood samples were collected after tail clipping using microhematocrit microcapillary tubes. Circulating Treg cells were then analyzed in a similar manner to splenic Treg cells. To analyze lung macrophages, cells were incubated with aqua-fixable LIVE-DEAD stain according to the manufacturer's protocol and then immunostained for CD11b, Siglec F, F4/80, and CD11c. For phospho-STAT3 flow cytometry, cells were fixed with 2% paraformaldehyde for 15 min at room temperature, permeabilized with 0.2% tween-20 for 10 min at room temperature, washed with permeabilization buffer, and then incubated with phospho-(Y705)-STAT3 antibody, and, in some cases, also total STAT3 antibody. Samples were processed on a BD FACSCanto II or BD Fortessa and analyzed with FlowJo software.
Regulatory T Cell Isolation
Spleens were collected from WT, Il10 À/À , or Il13 À/À mice and processed into a single cell suspension. CD4 + T cells were first enriched using the EasySep Mouse CD4 + T cell enrichment kit according to the manufacturer's instructions. CD4 + CD25 + T cells were then purified using the mouse CD25 regulatory T cell positive selection kit. Purity was assessed by flow cytometry analysis and cells were typically >93% CD4 + CD25 + .
In Vitro Efferocytosis Assay
In vitro efferocytosis assays were performed according to established protocols (Subramanian et al., 2014) . Primary bone marrowderived macrophages were cultured at 3 3 10 5 cells per well in 24-well tissue culture plates. To carry out efferocytosis, macrophages were incubated for 2 hr with PKH26-labeled Jurkat cells that were rendered apoptotic by UV-irradiation (Subramanian et al., 2014) at a ratio of 5:1 apoptotic cells: macrophage. Cultures were then vigorously washed, and fluorescence and bright field images were taken on an Olympus IX-70 microscope to identify uptake of labeled cells. Images were quantified using ImageJ software. A similar protocol was used to assay efferocytosis by human monocyte-derived macrophages. In the case of macrophage and Treg cell co-cultures, Treg cells were isolated as described above and then cultured with macrophages for $40 hr at a ratio of 1:4 (Treg cell:macrophage) in the presence of anti-CD3 (62.5 ng/mL). For rIL-10 or rIL-13 treatment, macrophages were exposed
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were tested for normality using the Kolmogorov-Smirnov test, and statistical significance was determined using GraphPad Prism software. Data that passed the normality were analyzed using Student's t test for two groups with one variable tested and equal variances, one-way ANOVA with Tukey's post-test for multiple groups with only variable tested, or two-way ANOVA with Sidak's post-tests for more than two groups with multiple variables tested. Data that were not normally distributed but contained equal variances were analyzed using the nonparametric Mann-Whitney U test with post hoc analysis. Data are shown as mean values ± SEM. Differences were considered statistically significant at p < 0.05.
